1Davie N,Holeen SJ,Upton PD,et al.ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells[J].Am J Respir Crit Care Med,2002,165(3):398-405.
2Kenneth M.Hemodynamic effect of PGE in patients with congential heart disease and pulmonary hypertension[J].Cathet Cardiovasc Diagn,1991,24(1):10-11.
3Ono S,Tanita T,Hoshikawa Y,et al.Effects of prostaglandin E1 on pulmonary hypertension and lung vascular remodeling in a rat monocrotaling midel of human pulmonary hypertension[J].Nippon Kyobu Shikkan Gakkai Zashi,1995,33 (8):862-864.
4Bouzas B,Gatzonlis MA.Pulmonary arterial hypertension in adults with congenital heart disease[J].Rev Esp Cardiol,2005,58(5):465-469.
5Shen J,He B,Wang B.Effects of lipo-prostaglandin E on pulmonary hemodynamics and chinical outcomes in patients with pulmonary arterial hypertension[J].Chest,2005,128(2):714-719.
6Hoffman TM,Wernovsky G,Atz AM,et al.Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease[J].Circulation,2003,107(7):996-1002.
7Felker GM,Benza RL,Chandler AB,et al.Heart failure etiology and response to milrinone in decompensated heart failure:results from the OP-TIME-CHF study[J].J Am Coll Cardiol,2003,41(6):997-1003.
8Zhang W,Ke H,Colman RW.Identification of interaction sites of cyclic nucleotide phosphodiesterase type 3A with milrinone and cilostazol using molecular modeling and site-directed mutagenesis[J].Mol Pharmacol,2002,62(3):514-520.
9Mikawa K,AkamatsuH,Nishina K,et al.The effect of phosphodiesterase III inhibitors on human neutrophil function[J].Crit Care Med,2000,28(4):1001-1005.
10Heerdt PM,Weiss CI.Prostaglandin E1 and intrapulmonary shunt in cardiac surgical patient with pulmonary hypertension[J].Ann Thorac Surg,1990,49 (3):463-465.
